



2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents

Jørn Herrstedt^{1,2} · L Celio³ · PJ Hesketh⁴ · L Zhang⁵ · R Navari⁶ · A Chan⁷ · M Saito⁸ · R Chow⁹ · M Aapro¹⁰

Published online: 21 December 2023
© The Author(s) 2023

Abstract

Purpose This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016–2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of ≥ 1500 mg/m² and the combination of cyclophosphamide and an anthracycline (AC) in women with breast cancer.

Methods A systematic review report following the PRISMA guidelines of the literature from January 1, 2015, until February 1, 2023, was performed. PubMed (Ovid), Scopus (Google), and the Cochrane Database of Systematic Reviews were searched. The literature search was limited to randomized controlled trials, systematic reviews, and meta-analyses.

Results Forty-six new references were determined to be relevant. The main topics identified were (1) steroid-sparing regimens, (2) olanzapine-containing regimens, and (3) other issues such as comparisons of antiemetics of the same drug class, intravenous NK₁ receptor antagonists, and potentially new antiemetics. Five updated recommendations are presented.

Conclusion There is no need to prescribe steroids (dexamethasone) beyond day 1 after AC HEC, whereas a 4-day regimen is recommended in non-AC HEC. Olanzapine is now recommended as a fixed part of a four-drug prophylactic antiemetic regimen in both non-AC and AC HEC. No major differences between 5-HT₃ receptor antagonists or between NK₁ receptor antagonists were identified. No new antiemetic agents qualified for inclusion in the updated recommendations.

Keywords High-emetic-risk chemotherapy · HEC · Antiemetics · Nausea · Vomiting · Guideline

Introduction

The risk of nausea and vomiting following antineoplastic therapy depends on the emetic risk potential of the antineoplastic therapy, patient demographics such as sex (women

are at a higher risk than men) and age (younger patients have a higher risk than older), and the antiemetic prophylaxis prescribed.

The emetic risk of antineoplastic agents administered intravenously (i.v.) is defined as the risk of vomiting within the first 24 h after the start of antineoplastic therapy in

Celio L is an independent medical oncologist.

✉ Jørn Herrstedt
jherr@regionsjaelland.dk

¹ Department of Clinical Oncology, Zealand University Hospital, Sygehusvej 10, DK-4000 Roskilde, Denmark

² Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

³ Milan, Italy

⁴ Division of Hematology Oncology, Lahey Hospital and Medical Center, Burlington, MA, USA

⁵ State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

⁶ World Health Organization, Birmingham, Alabama, USA

⁷ Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA

⁸ Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan

⁹ Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

¹⁰ Genolier Cancer Center, Genolier, Switzerland

patients who did not receive antiemetic prophylaxis. High emetic risk is defined as a risk of more than 90% of vomiting. High-emetic-risk antineoplastic agents administered intravenously include cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of $\geq 1500 \text{ mg/m}^2$ and the combination of cyclophosphamide and an anthracycline (AC) in women with breast cancer. All these are chemotherapeutic agents and are referred to as high-emetic-risk chemotherapy (HEC).

Very few data on the emetic risk potential of orally administered antineoplastic agents exist, and the emetic risk potential refers to the risk during the entire treatment period rather than the first 24 h.

This manuscript is a systematic review and update of the MASCC/ESMO recommendations for high-emetic-risk antineoplastic agents published in 2016–2017 [1, 2].

Methods

A literature search was conducted from January 1, 2015, through February 1, 2023. PubMed (Ovid), Scopus (Google), and the Cochrane Database of Systematic Reviews were searched. The reporting of literature search followed the PRISMA guidelines [3]. The seven HEC agents were used as keywords and paired with each of the available antiemetics within the five antiemetic drug groups (neurokinin (NK)₁ receptor antagonists, serotonin (5-HT)₃ receptor antagonists, corticosteroids, dopamine (D)_{2,3} receptor antagonists, and cannabinoids). For example, the search terms for cisplatin were as follows: cisplatin AND aprepitant OR netupitant OR rolapitant OR fosaprepitant OR fosnetupitant OR neurokinin antagonist; cisplatin AND ondansetron OR granisetron OR palonosetron OR ramosetron OR serotonin antagonist; cisplatin AND dexamethasone or methylprednisolone or prednisolone or steroid; cisplatin AND metoclopramide OR domperidone OR metopimazine OR prochlorperazine OR olanzapine OR amisolpride OR dopamine antagonist; cisplatin AND cannabis OR tetrahydrocannabinol OR nabilone OR dronabinol OR cannabidiol OR cannabinoid. The search was limited to randomized controlled trials, systematic reviews, and meta-analyses. The number of results identified from literature search and determined to be relevant is summarized as a PRISMA flow diagram in Fig. 1. For the distribution of selected references in each of the antiemetic drug groups, see Table 1.

Results

A total of 80 references were identified as relevant for further full-text review after reading abstracts of all 1058 references. The 80 references were distributed as follows:

NK₁ receptor antagonist ($n = 25$), 5-HT₃ receptor antagonists ($n = 35$), D_{2,3} receptor antagonists ($n = 14$), corticosteroids ($n = 6$), and cannabinoids ($n = 0$). After removal of duplicates, 46 references qualified for consideration by the guideline committee, in the context of updating this guideline [2, 4–48]. The references were divided into three categories according to the quality of the study and the potential to change the guideline.

Category 1 [4, 9, 12, 13, 20, 22, 24, 25, 30, 34, 38, 39, 41, 44, 48]:

References have the potential to change the guidelines and are described in detail in the manuscript.

Category 2: [5–8, 10, 11, 14, 15, 17–19, 21, 23, 26–28, 31–33, 35–37, 40, 42, 43, 45, 47]:

References are supportive for category 1 references and are described briefly in the manuscript.


Category 3 [3, 16, 29, 46]:

References about new agents or minor studies in new settings may be hypothesis generating. These references are mentioned in the manuscript.

The main topics identified were (1) steroid-sparing regimens, (2) olanzapine-containing regimens, and (3) other issues such as comparisons of antiemetics of the same drug class, intravenous NK₁ receptor antagonists, and potentially new antiemetics.

Steroid-sparing regimens

The literature search identified six references qualifying for inclusion in the current update. These included two original studies [8, 22], a combined analysis of these two studies [7], a sub-analysis [6] of one of the studies [8], and two meta-analyses [5, 31] of which one [31] included a systematic review. A meta-analysis from 2019 including eight studies concluded that a single day of dexamethasone (DEX) is as good as a 3-day regimen in patients receiving moderately emetogenic chemotherapy (MEC) or AC chemotherapy [5]. Another systematic review and meta-analysis from 2019 including five studies and using a non-inferiority margin of -8% confirmed non-inferiority of a 1-day DEX regimen compared to a 3-day DEX regimen in MEC and AC patients [31]. This was further investigated in a randomized, double-blinded, placebo-controlled, non-inferiority trial including 396 patients [22]. Patients in this trial received cisplatin-based ($\geq 50 \text{ mg/m}^2$) or AC chemotherapy. Patients were randomized to receive either DEX day 1 (12 mg i.v.) plus placebo days 2–3 or DEX 12 mg i.v. day 1 followed by DEX 8 mg days 2–3. All patients

Fig. 1 Flowchart literature search: HEC and antiemetics

also received palonosetron 0.75 mg i.v. plus aprepitant 125 mg p.o. day 1 followed by 80 mg p.o. days 2–3 or fosaprepitant 150 mg i.v. day 1. Patients were stratified for age and chemotherapy (cisplatin versus AC). The primary end point was complete response (CR) in the overall period (defined as no emetic episodes and no use of rescue medication days 1–5 after chemotherapy), and the non-inferiority margin was 15%. CR was 46.9% (3 days of DEX) versus 44% (1 day of DEX),

$p = 0.007$ (95% CI, -12.6 to 6.8%). A subgroup analysis of patients receiving AC confirmed non-inferiority of the 1-day DEX regimen, whereas non-inferiority was not confirmed in patients receiving cisplatin-based chemotherapy. In a multi-center, randomized, open-designed, non-inferiority, three-arm study, Celio et al. investigated chemotherapy-naïve patients who received their first course of cisplatin-based (≥ 70 mg/m²) chemotherapy [8]. All patients received oral NEPA (netupitant

Table 1 Status literature search high-emetic-risk antiemetic agents

Antiemetic drug group	References included in the 2023 update	Final number (duplicates deleted)
NK ₁ receptor antagonist	25	46
5-HT ₃ receptor antagonist	35	
Dopamin _{2,3} receptor antagonists and multi-receptor targeting agents (e.g., olanzapine)	14	
Corticosteroids	6	
Cannabinoids	0	
Total	80	

300 mg plus palonosetron 0.5 mg) and DEX 12 mg i.v. before chemotherapy and were randomized to no DEX days 2–4 (DEX1), oral DEX 4 mg × 1 days 2–3 (DEX3), or oral DEX 4 mg × 2 on days 2–4 (DEX4). The primary endpoint was CR (defined as above) in the overall phase. The study was powered (80%) not to overlook differences larger than 15%. Non-inferiority was confirmed for the DEX1 arm compared to the DEX4 arm (95% CI, –12.3 to 15%). The authors reported that a limitation was the open design and that only 33% of the patients were women. Furthermore, the overall CR in the control arm was lower (75%) than estimated in the patient sample size calculation (90%). It is important to note that none of the above studies included olanzapine as an antiemetic. It may be possible that the addition of olanzapine to a three-drug DEX-sparing regimen would be non-inferior to a conventional 4-day DEX regimen in patients treated with cisplatin. In fact the SPARED study [29] suggests that this may be possible; although results were presented as a late breaking abstract at the annual ESMO congress in 2021 [49], full publication is not available at the time of the update (September 2023).

Olanzapine-containing regimens

Nine references evaluating olanzapine qualified for inclusion in the update. These consisted of two systematic reviews [2, 18] and seven randomized, controlled trials [11, 13, 21, 30, 38, 41, 43] of which all but one [43] used a double-blind design.

Olanzapine as an add-on to a three-drug regimen

Two large phase 3 studies compared the addition of olanzapine to the standard antiemetic regimen of a 5-HT₃ receptor antagonist plus DEX plus an NK₁ receptor antagonist. Navari et al. completed a randomized, double-blind trial comparing a 5-HT₃ receptor antagonist plus DEX plus aprepitant/fosaprepitant plus placebo with the same 3-drug regimen plus oral olanzapine 10 mg once daily on days 1–4 after chemotherapy. The study included 380 chemotherapy-naïve patients receiving either cisplatin-based (≥ 70 mg/m²) or AC

chemotherapy [30]. Patients were stratified for sex, chemotherapy (cisplatin-based versus AC), and the specific 5-HT₃ receptor antagonist (palonosetron, granisetron, and ondansetron). The primary end point was no nausea (defined as 0 mm on a visual analogue scale during the overall assessment period from 0 to 120 h after chemotherapy). CR (defined as no emetic episodes and no need of rescue medication from 0 to 120 h after chemotherapy), no acute nausea (0–24 h), and no delayed nausea (24–120 h) were all secondary endpoints. No nausea was significantly more frequent in the olanzapine group than in the placebo group, with no nausea rates of 74% versus 45% (0–24 h, $p = 0.002$), 42% versus 25% (24–120 h, $p = 0.002$), and 37% versus 22% (0–120 h, $p = 0.002$). Also the number of patients with CR was significantly higher in the olanzapine group (86% versus 65%, 67% versus 52%, and 64% versus 41% in the acute, delayed, and overall phases, respectively). Sedation was more frequent in the olanzapine group, but both antiemetic regimens were well tolerated. Hashimoto et al. completed a similar double-blind study in chemotherapy-naïve patients receiving cisplatin-based (≥ 50 mg/m²) chemotherapy, but used olanzapine 5 mg daily for 4 days (instead of 10 mg as in the Navari study), and all patients received palonosetron (0.75 mg × 1 i.v.) as the preferred 5-HT₃ receptor antagonist in combination with DEX and aprepitant/fosaprepitant [12, 13]. The study included 705 evaluable patients, and stratification was done for sex, dose of cisplatin, and age. The primary end point was CR in the delayed phase (24–120 h after cisplatin). Olanzapine significantly improved the number of patients with CR in the delayed phase ([79%; 95% CI 75–83] versus [66%; 95% CI 61–71], $p < 0.0001$), but also in the acute and overall phases (secondary end points). Furthermore, the number of patients obtaining complete control (defined as CR and no more than mild nausea) and total control (defined as CR and no nausea) was also significantly higher in the olanzapine group. Sedation was not significantly more frequent in the olanzapine group, and the authors concluded that this was due to the lower dose of olanzapine and the administration after dinner (instead of the usual dosing in the morning). A third, randomized, double-blind study ($n = 208$) compared olanzapine

5 mg p.o daily for 4 days with placebo in chemotherapy-naïve patients with breast cancer receiving four cycles of neoadjuvant or adjuvant AC (90%) or cyclophosphamide (non-anthracycline)-based (10%) chemotherapy. All patients, in addition to olanzapine/placebo, received aprepitant, ondansetron, and DEX. The primary end point was self-reported nausea and secondary end points were control of acute and delayed nausea and vomiting [11]. Olanzapine significantly reduced the number of patients reporting nausea during all four cycles (27.7% versus 41.3%, $p < 0.001$), whereas the number of vomiting episodes was not statistically significantly reduced. Mild sedation was more frequent in the olanzapine group (54.1% versus 40.8%, $p < 0.001$).

Finally, a randomized, open, study ($n = 120$) in chemotherapy-naïve Chinese breast cancer patients receiving neoadjuvant or adjuvant AC chemotherapy compared aprepitant, ondansetron, and DEX with or without the addition of olanzapine 10 mg p.o. once daily for 5 days [43]. The authors concluded that addition of olanzapine increased the number of patients with CR (no vomiting and no use of rescue medication), the rates of no nausea (nausea on a visual analogue scale (VAS) < 5 mm), and no significant nausea (nausea VAS < 25 mm).

Dose and schedule of olanzapine

The most frequent adverse effect of olanzapine is sedation which could be severe in older patients [50]. The vast majority of studies ($n \approx 30$) have investigated olanzapine in a dose and schedule of 10 mg once daily for 4 days usually administered during daytime [10, 30, 43, 51, 52]. A number of studies ($n \approx 15$) have investigated olanzapine in a dose of 5 mg once daily [13, 48, 53, 54], and in some of these ($n \approx 10$), olanzapine was administered at bedtime to avoid or diminish sedation [13, 48]. A few studies ($n \approx 10$) have compared 5 mg and 10 mg of olanzapine [21, 38, 41], but none of these studies used guideline-recommended methodology or included a sufficient number of patients in order to conclude the benefits and harms between 5 mg and 10 mg [55]. A review from 2022 concluded that the evidence for administration at bedtime remains weak [56], and still no comparisons with daytime administration have been done.

Other issues

Comparison of different 5-HT₃ receptor antagonists

Two studies compared the 5-HT₃ receptor antagonist ramosetron with palonosetron [23] and ondansetron [26], respectively. In a single-blind non-inferiority study, 279 patients were treated with cisplatin-based (72%) or AC-based (28%) chemotherapy, and all received aprepitant (days 1–3) and DEX (days 1–4) for antiemetic protection and were

randomized to ramosetron 0.3 mg i.v. or palonosetron 0.25 mg i.v. on day 1. Ramosetron was non-inferior to palonosetron, with respect to the primary end point of complete response (no emesis and no rescue antiemetics in the first 5 days after chemotherapy) and all secondary end points. No differences in adverse events were observed [23]. In another single-blind study [26] with a similar design, 299 patients treated with cisplatin-based or AC-based chemotherapy all received aprepitant and DEX and were randomized to ramosetron 0.3 mg i.v. or ondansetron 16 mg i.v. on day 1. Ramosetron was non-inferior to ondansetron, but the interpretation of the results was confounded by a significant difference in the number of women allocated to ramosetron (20.8%) and ondansetron (41.9%), because it is well known that the female sex increases the risk of CINV.

Two studies compared outcomes between granisetron and palonosetron [27, 40]. In a randomized, double-blind trial, 842 patients treated with cisplatin-based (≥ 50 mg/m²) chemotherapy all received aprepitant (days 1–3) and DEX (days 1–4) and were randomized to palonosetron 0.75 mg i.v. (day 1) or granisetron 1 mg i.v. (on day 1). The study had 90% power to detect differences larger than 10%. The primary end point was CR (no emesis and no rescue antiemetics) in the first 120 h after chemotherapy. CR was not statistically significant different between the palonosetron (65.7%) and granisetron (59.1%) arms (95% CI 1.35 (0.99–1.82), $p = 0.0539$). A number of secondary end points favored palonosetron in the delayed phase (24–120 h after cisplatin), but differences were all less than 10% [40]. A randomized, double-blind study compared the effect of palonosetron 0.75 mg i.v. on day 1 against granisetron 1 mg i.v. on day 1, with both arms combined with fosaprepitant 150 mg i.v. on day 1 and DEX days 1–3 in women with breast cancer treated with AC-based chemotherapy [27]. The study included 326 patients, and the primary end point was CR (no emesis and no rescue antiemetics) in the delayed phase (24–120 h after chemotherapy). No significant differences in CR (24–120 h) were seen (CR granisetron 60.4% versus 62.3% palonosetron, $p = 0.8$) or in acute (0–24 h) or overall CR (0–120 h). An open, randomized study with a high dropout rate (18.3%) concluded that granisetron (transdermal administration) was non-inferior to ondansetron i.v., and both arms combined with aprepitant and DEX in patients receiving highly emetogenic chemotherapy [39].

A systematic review and meta-analysis published in 2021 [20] included 12 studies and concluded that palonosetron was superior to granisetron, but in a sub-analysis of the only three studies [27, 40, 57] including an NK₁ receptor antagonist, this advantage disappeared with the exception of a minor advantage of palonosetron CR in the delayed phase (95% CI 1.30 (1.02–1.64)). However, it should be noted that olanzapine was not included in any of the above studies or in the systematic review.

New studies of i.v. NK₁ receptor antagonists and comparison of different NK₁ receptor antagonists

There are differences between the intravenous formulations of the NK₁ receptor antagonists.

An injectable emulsion of rolapitant was approved by FDA in 2017, but due to serious hypersensitivity reactions [58], the rolapitant emulsion approval was withdrawn in January 2021 [59]. Fosaprepitant was already proven non-inferior to aprepitant and described in the 2016 guidelines [2]. Non-inferiority was recently confirmed in two large studies in Chinese patients receiving HEC, primarily cisplatin-based chemotherapy [42, 60]. Fosaprepitant induces injection site reactions (ISRs) in a small number of patients, in particular those receiving AC-based chemotherapy. Another intravenous formulation of aprepitant (HTX-019, an injectable emulsion of aprepitant free of polysorbate 80) has a lower incidence of ISRs [59, 61, 62]. In a large phase 2 study ($i = 584$), fosnetupitant (two different doses) was compared with placebo both combined with palonosetron and DEX in patients receiving cisplatin-based (≥ 70 mg/m²) chemotherapy [37]. The high dose of fosnetupitant (235 mg) significantly improved the antiemetic effect of palonosetron and DEX as compared to placebo, and no significant differences in adverse events were observed. This confirmed results from a previous study by Hesketh et al. already reviewed in the 2016 guidelines [2]. Schwartzberg and colleagues compared intravenous NEPA (fosnetupitant and i.v. palonosetron) with oral NEPA both combined with DEX in two randomized, double-blind studies in patients receiving cisplatin-based ($n = 404$) and AC-based ($n = 402$) chemotherapy, respectively [35, 36]. The primary end point was safety and tolerability, and both studies included a multiple cycle extension ($n = 4$). It was concluded that there was no difference between i.v. and oral NEPA as concerns antiemetic efficacy or safety. It is noteworthy, that no significant differences were observed in ISRs.

Three studies compared a (fos)netupitant-based regimen against a (fos)aprepitant-based antiemetic regimen [14, 28, 45]. In a large randomized, double-blind, non-inferiority, phase 3 study ($n = 828$), oral NEPA and DEX were compared to aprepitant, granisetron, and DEX in patients receiving cisplatin-based (≥ 50 mg/m²) chemotherapy [45]. The primary end point was CR (defined as no emesis and no rescue antiemetics) during the first 120 h after start of cisplatin. Non-inferiority was demonstrated for acute CR (0–24 h), delayed CR (24–120 h), overall CR (0–120 h), and for no emesis; no nausea (< 5 mm on a 0–100 mm VAS) and no significant nausea (< 25 mm) both in the acute, delayed, and overall phases. A secondary (preplanned) analysis of the Chinese subpopulation (80.6%) confirmed these results [9]. Another randomized, double-blind, non-inferiority, phase 3 study ($n = 785$) compared fosnetupitant with fosaprepitant

both combined with palonosetron and DEX in patients receiving cisplatin-based (≥ 70 mg/m²) chemotherapy [14]. Non-inferiority was proven for all efficacy end points. There were no differences in adverse effects with the exception of ISR, which was more frequently observed with fosaprepitant. Finally, a small randomized, double-blind, phase 3 study ($n = 102$) compared fosnetupitant with fosaprepitant both combined with palonosetron and DEX in patients treated with AC/EC chemotherapy [28]. The primary end point was the incidence of treatment-related adverse events (TRAEs), whereas efficacy end points were secondary. No significant differences in TRAEs were seen with the exception of TRAEs relevant for ISRs observed in 0% of the fosnetupitant patients, compared to 10% of fosaprepitant patients. It should be noted that none of the above studies compared fosnetupitant with HTX-019 aprepitant emulsion that has a lower risk of ISRs than fosaprepitant [59, 61, 62].

Potential new antiemetics

A few studies have investigated other drugs for the protection of nausea and vomiting in HEC [4, 16, 46]. In a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study ($n = 318$), the dopamine D₃ receptor antagonist, amisulpride, improved the antiemetic effect of ondansetron in chemotherapy-naïve patients treated with cisplatin-based (≥ 70 mg/m²) chemotherapy [16]. A single oral dose of 10 mg days 2–4 was significantly superior to placebo as concerns the primary end point, delayed CR (no emesis and no rescue antiemetics 24–120 h after start of chemotherapy) obtained in 46% versus 20% of patients ($p = 0.002$) and the secondary end point, delayed no nausea rate (< 5 mm on a 100 mm VAS) obtained in 37% versus 19% ($p = 0.016$). No significant differences in adverse effects (including sedation) was seen. An open-label study ($n = 100$, closed prematurely due to slow recruitment) investigated the antiemetic effect of the atypical tetracyclic antidepressant, mirtazapine, with affinity for multiple receptors (serotonin, histamine, adrenergic). The study indicated that mirtazapine can improve the effect of aprepitant, palonosetron, and DEX on delayed emesis in women treated with cisplatin-based chemotherapy or EC and who experienced delayed emesis in the preceding chemotherapy cycle [4].

Thalidomide was investigated in a large randomized, double-blind trial ($n = 638$) in chemotherapy-naïve patients scheduled to receive their first course of cisplatin-based (≥ 50 mg/m²) or AC/EC chemotherapy [46]. Patients received palonosetron on day 1 and DEX on days 1–4 and were randomized to oral thalidomide 100 mg twice daily on days 1–5 or placebo. The primary end point was CR (25–120 h after start of chemotherapy). Thalidomide significantly improved the rates of CR in the delayed and overall phases (76.9% versus 61.7%, $p < 0.001$ and 66.1% versus 53.3%, p

Table 2 2023 updated MASCC-ESMO recommendations high emetic risk chemotherapy

Question	Recommendation	Note	Level of evidence	Grade of recommendation
How to prevent acute nausea and vomiting following non-AC chemotherapy of high emetic risk (HEC)?	A four-drug regimen including single doses of a 5-HT ₃ receptor antagonist, dexamethasone (DEX), an NK ₁ receptor antagonist (aprepitant, fosaprepitant, netupitant*, fosnetupitant* or rolapitant), and olanzapine given before chemotherapy is recommended	*Netupitant/fosnetupitant is administered with palonosetron as part of the fixed-dose combination agent NEPA	I	A
How to prevent delayed nausea and vomiting following non-AC HEC?	In patients receiving non-AC HEC treated with a combination of a 5-HT ₃ receptor antagonist, DEX*, an NK ₁ receptor antagonist**, and olanzapine to prevent acute nausea and vomiting, DEX and olanzapine on days 2 to 4 is suggested to prevent delayed nausea and vomiting (see note about DEX dosing)	* A few studies have investigated a 1-day DEX regimen as an option in cisplatin with one study demonstrating comparable efficacy between a 1-day and multi-day DEX schedules ** If aprepitant 125 mg is used on day 1, then aprepitant 80 mg × 1 should be administered on days 2–3	II	B
How to prevent acute nausea and vomiting following anthracycline-cyclophosphamide (AC)-based chemotherapy of high emetic risk?	In women treated with AC-based chemotherapy, a four-drug regimen including single doses of a 5-HT ₃ receptor antagonist, DEX, an NK ₁ receptor antagonist (aprepitant, fosaprepitant, netupitant*, fosnetupitant* or rolapitant), and olanzapine given before chemotherapy is recommended	This recommendation is based on extensive data in women treated with adjuvant AC for breast cancer *Netupitant/fosnetupitant is administered with palonosetron as part of the fixed-dose combination agent NEPA	I	A
How to prevent delayed nausea and vomiting following anthracycline-cyclophosphamide (AC)-based chemotherapy of high emetic risk?	In women treated with a combination of a 5-HT ₃ receptor antagonist, DEX, an NK ₁ receptor antagonist*, and olanzapine to prevent acute nausea and vomiting, olanzapine on days 2 to 4 is suggested to prevent delayed nausea and vomiting	This recommendation is based on extensive data in women treated with adjuvant AC for breast cancer *If aprepitant 125 mg is used on day 1, then aprepitant 80 mg × 1 should be administered on days 2–3	II	B
Which dose and schedule of olanzapine is to be preferred in the prevention of acute and delayed nausea and vomiting following chemotherapy of high emetic risk?	The best investigated dose is 10 mg. 5 mg is superior to placebo, but it is unknown if it is as effective as 10 mg, because no robust studies have compared the 5 mg and 10 mg doses. The only schedule investigated is once daily for 4 days (see note about sedation)	If sedation is a concern, a starting daily dose of 5 mg and/or administration at bedtime is an option	II	B

= 0.001, respectively). Dizziness, constipation, sedation, and dry mouth were adverse events more frequently observed with thalidomide, whereas insomnia was more frequent in the placebo-treated patients.

Discussion

This systematic review is the result of a literature search, reported in accordance with the PRISMA guidelines for systematic reviews, and the review and discussions of the references relevant for the guideline update. One face-to-face meeting and five virtual meetings provided the background for the literature review and update of the guideline recommendations. The recommendations are summarized in Table 2.

There is level I evidence to limit dosing of dexamethasone to day 1 after AC chemotherapy. For patients receiving cisplatin-based (and other non-AC HEC), results are inconclusive and the 2016 recommendation of a 3–4 day DEX regimen stands. None of the studies defined in the literature search included olanzapine, except for the SPARED study [29, 49]; however, at the time of this review writing (September 2023), it is published as an abstract only and therefore not considered in this update. It is possible, that the addition of olanzapine makes it possible to limit the administration of dexamethasone to day 1 also in patients receiving cisplatin-based chemotherapy [63].

The addition of olanzapine to a three-drug regimen of a 5-HT₃ receptor antagonist an NK₁ receptor antagonist and DEX was optional in the 2016 MASCC/ESMO guidelines. Recently, large, well-conducted studies [13, 30] delivered clear evidence that olanzapine improves outcomes of the above three-drug regimen and olanzapine is now recommended as a fixed part of a four-drug regimen. This is in line with the ASCO recommendations [17, 18]. Sedation is an adverse event and could be a problem in older patients. Therefore, lower doses of olanzapine and administration at bedtime have been investigated. Unfortunately comparative studies (of olanzapine 10 mg and 5 mg) are few and not sufficiently powered to conclude if the 5-mg dose is as effective as the 10-mg dose [64] (Table 2). No new significant differences between the 5-HT₃ receptor antagonists have been disclosed in this review. It is possible that palonosetron exhibits a small advantage in the protection of delayed nausea and vomiting if an NK₁ receptor antagonist is not available or affordable [20].

Across the different NK₁ receptor antagonists, no new difference were disclosed. This means that there are minor differences in the pharmacology (e.g., half-life and risk of drug-drug interactions), but this has not resulted in major

differences in the effect or tolerability. The i.v. formulations of fosnetupitant [14, 28] and the HTX-019 emulsion of aprepitant [59, 61, 62] both seem to have a very low risk of ISRs.

No new antiemetics qualified for inclusion in the guideline update. Two agents (amisulpride and mirtazapine) were investigated and seemed to possess antiemetic efficacy in HEC patients, but none of the studies included guideline-recommended antiemetic regimens [4, 16]. A third study concluded that thalidomide improves the effect palonosetron and DEX in patients treated with HEC, but again an NK₁ receptor antagonist (or olanzapine) was not included and concerns about adverse events have been raised [65].

Finally, although not part of this review, it is concluded that in spite of the major contribution from olanzapine in reducing nausea, this adverse event remains the major CINV problem in HEC patients.

Author contributions All authors contributed to the literature search.

All authors reviewed the references disclosed from the literature search

In particular the literature on steroids was reviewed by LC and MA, the literature on 5-HT₃-receptor antagonists by LZ and JH, the literature on NK₁-receptor antagonists by PJH, RC and JH, the literature on dopamine-receptor antagonist by RMN and JH, the literature on cannabinoids by MA and JH and the literature on pharmacological issues by MS and AC.

JH drafted the manuscript. No medical writer was included in the manuscript writing.

All authors commented on the draft manuscript.

All authors approved the final manuscript.

Funding Open access funding provided by Copenhagen University. The Multinational Association of Supportive Care in Cancer and the European Society for Medical Oncology funded participation in a consensus meeting in Toronto June 2022.

No other funding was received.

Declarations

Ethics approval Not relevant

Consent to participate Not relevant

Competing Interests Jørn Herrstedt (JH) declares that he has received honoraria from PharmaThen S.A.

Luigi Celio (LC) has received consulting fees Italfarmaco; speaker's fee Berlin-Chemie AG.

Paul J Hesketh (PJH) declares that he has no financial interests.

Li Zhang (LZ) declares that he has no financial interests.

Rudolph M Navari (RMN) declares that he has no financial interests.

Alexandre Chan (AC) declares that he has no financial interests.

Mitsue Saito (MS) declares that she has no financial interests.

Ronald Chow (RC) declares that he has no financial interests.

Matti Aapro (MA) declares the following interests relevant to this manuscript: has received honoraria from Berlin-Chemie, Fosun, Helsinn Healthcare SA, Juniper Biologics, Knight Therapeutics, Mundipharma International Limited, Vifor Pharma.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. RRoila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M on behalf of the participants of the MASCC/ ESMO Consensus Conference Copenhagen (2015) 2016 MASCC/ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. *Ann Oncol* 27(Supplement 5):v119–v133. <https://doi.org/10.1093/annonc/mdw270>
2. Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. *Support Care Cancer* 25:277–288. <https://doi.org/10.1007/s00520-016-3313-0>
3. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB, PRISMA-S Group (2021) PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. *Syst Rev* 10:39. <https://doi.org/10.1186/s13643-020-01542-z>
4. Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y, Wang B, Wang Z, Zhang J, Wang L, Wu J, Shao Z, Hu X (2020) Mir tazapine, a dopamine receptor inhibitor, as secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy; an open label, randomized, multicenter phase III trial. *Invest New Drugs* 38:507–514. <https://doi.org/10.1007/s10637-020-00903-8>
5. Celio L, Bonizzoni E, Zattarin E, Codega P, de Braud F, Aapro M (2019) Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately and highly emetogenic chemotherapy: a meta-analysis of randomized evidence. *BMC Cancer* 19:1268. <https://doi.org/10.1186/s12885-019-6454-y>
6. Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S et al (2022) Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. *BMC Cancer* 22:915. <https://doi.org/10.1186/s12885-022-10018-3>
7. Celio L, Bonizzoni E, Montani E, Aapro M (2022) Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis. *Future Oncol* 18:3389–3397. <https://doi.org/10.2217/fon-2022-0330>
8. Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S et al (2021) Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study. *Oncologist* 26:e1854–e1861. <https://doi.org/10.1002/onco.13851>
9. Chang J, Chen G, Wang D, Wang G, Lu S, Feng J, Li W, Li P, Lanzarotti C, Chessari S, Zhang L (2020) Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy in a randomized phase 3 study. *Cancer Med* 9:5134–5142. <https://doi.org/10.1002/cam4.3123>
10. Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: The FOND-O trial. *Biol Blood Marrow Transplant* 24:2065–2071. <https://doi.org/10.1016/j.bbmt.2018.06.005>
11. Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A, Mates M, Hsu T, McGee S, Freedman O, Kumar V, Fergusson D, Hutton B, Vandermeer L, Hilton J (2020) A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. *Breast* 54:278–285. <https://doi.org/10.1016/j.breast.2020.11.002>
12. Hashimoto H, Abe M, Yanai T, Yamaguchi T, Zenda S, Uchitomi Y, Fukuda H, Mori M, Iwasa S, Yamamoto N, Ohe Y (2018) Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double-blind, placebo-controlled phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy. *Jpn J Clin Oncol* 48:950–952. <https://doi.org/10.1093/jjco/hyy114>
13. Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 21:242–249. [https://doi.org/10.1016/S1470-2045\(19\)30678-3](https://doi.org/10.1016/S1470-2045(19)30678-3)
14. Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T (2022) Randomized, double-blind phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. *J Clin Oncol* 40:180–188. <https://doi.org/10.1200/JCO.21.01315>
15. He Mc XR, Liu M, Zhang Y, Yi F, Wei Y, Liu Q, Zhang W (2021) Use of dexamethasone and a 5-HT₃ receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of randomized controlled trials. *Ann. Palliat Med* 10:4308–4319. <https://doi.org/10.21037/apm-20-2290>
16. Herrstedt J, Summers Y, Jordan K, Pawel J von, Jakobsen AH, Ewertz M, Chan S, Naik JD, Karthaus M, Dubey S, Davis R, Fox GM. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled, dose-ranging trial. *Support Care Cancer* 2019 27:2699–2705. <https://doi.org/10.1007/s00520-018-4564-8>
17. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng

- C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *Clin Oncol* 35:3240–3261. <https://doi.org/10.1200/JCO.2017.74.4789>
18. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2020) Antiemetic: ASCO guideline update. *J Clin Oncol* 38:2782–2797. <https://doi.org/10.1200/JCO.20.01296>
 19. Hesketh PJ, Palmas M, Nicolas P (2018) Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic. *Support Care Cancer* 26:1151–1159. <https://doi.org/10.1007/s00520-017-3936-9>
 20. Hsu Y-C, Chen C-Y, Tam K-W (2021) Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. *Eur J Clin Pharmacol* 77:1597–1609. <https://doi.org/10.1007/s00228-021-03157-2>
 21. Ithimakin S, Theeratrakul P, Laocharoenkiat A, Nimmannit A, Akewanlop C, Soparattanapaisarn N, Techawattanawanna S, Korphaisarn K, Danchaivijitr P (2020) Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. *Support Care Cancer* 28:5335–5342. <https://doi.org/10.1007/s00520-020-05380-6>
 22. Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Fujuruya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S et al (2018) Placebo-controlled, double-blinded, phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. *J Clin Oncol* 36:1000–1006. <https://doi.org/10.1200/JCO.2017.74.4375>
 23. Kang JH, Kwon JH, Lee Y-G PKU, An HJ, Sohn J, Seol YM, Lee H, Yun H-J, Ahn JS, Yang JH, Song H, Koo D-H, Kim JY, Kim GM, Kim HJ (2020) Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly-emetogenic chemotherapy-induced nausea and vomiting. *Cancer Res Treat* 52:907–916. <https://doi.org/10.4143/crt.2019.713>
 24. Karthaus M, Voisin D, Rizzi G, Ciuleanu T (2020) Phase 3 study of palonosetron iv infusion vs iv bolus for chemotherapy-induced nausea and vomiting prophylaxis after highly emetogenic chemotherapy. *J Pain Symp Manag* 60:568–576. <https://doi.org/10.1016/j.jpainsymman.2020.03.034>
 25. Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM (2015) Efficacy and safety of oral palonosetron compared with iv palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). *Support Care Cancer* 23:2917–2923. <https://doi.org/10.1007/s00520-015-2657-1>
 26. Kim JH, Shin SW, Song E-K, Lee N-R, Kim JS, Ahn JS, Yun H-J, Cho Y-H, Park KU, Kim S-Y, Jang JS, Kim S-W, Lee HW, Lee SR, Kim YS, Lee SN, Ko YH, Kim HJ, Kang J-H (2015) Ramosetron versus ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a multicenter, randomized, phase III trial, KCSG PC10-21. *Oncologist* 20:1440–1447. <https://doi.org/10.1634/theoncologist.2015-0128>
 27. Matsumoto K, Takahashi M, Sato K, Osaki A, Takano T, Naito Y, Matsuura K, Aogi K, Fujiwara K, Tamura K, Baba M, Tokunaga S, Hirano G, Imoto S, Miyazaki C, Yanagihara K, Imamura CK, Chiba Y, Saeki T (2020) A Double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. *Cancer Med* 9:3319–3327. <https://doi.org/10.1002/cam4.2979>
 28. Matsuura K, Tsurutani J, Inoue K, Tanabe Y, Taira T, Kubota K, Tamura T, Saeki T (2022) A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide. *Cancer* 128:1692–1698. <https://doi.org/10.1002/encr.34088>
 29. Minatogawa H, Izawa N, Kawaguchi T, Miyaji T, Shimomura K, Kazunori H, Lihara H, Ohno Y, Inada Y, Arioka H, Morita H, Hida N, Sugawara M, Katada C, Nawata S, Ishida H, Tsuboya A, Tsuda T, Yamaguchi T, Nakajima TE (2020) Study protocol for SPARED trial: randomized, non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy. *BMJ Open* 17(10):e041737. <https://doi.org/10.1136/bmjopen-2020-041737>
 30. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. *New Engl J Med* 375:134–142. <https://doi.org/10.1056/NEJMoa1515725>
 31. Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, Komatsu Y, Celio L, Aapro M (2019) One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. *Oncologist* 24:1593–1600. <https://doi.org/10.1634/theoncologist.2019-0133>
 32. Patel P, Leeder JS, Piquette-Miller M, Dupuis LL (2017) Aprepitant and fosaprepitant drug interactions: a systematic review. *Br J Clin Pharmacol* 83:2148–2162. <https://doi.org/10.1111/bcp.13322>
 33. Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, Jordan K, Kuhr K, Skoetz N (2021) Antiemetics for adults for prevention of nausea and vomiting by moderately or highly emetogenic chemotherapy: a network meta-analysis (review). *Cochrane Database Syst Rev* 11:CD012775. <https://doi.org/10.1002/14651858.CD012775.pub2>
 34. Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE Jr, Taylor C, Wilks ST, Schwartzberg LS, Cooper W, Mosier MC, Payne JY, Klepper MJ, Vacirca JL (2016) APF530 (granisetron injection extended release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. *Future Oncol* 12:1469–1481. <https://doi.org/10.2217/fon-2016-0070>
 35. Schwartzberg L, Roland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M (2018) Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. *Ann Oncol* 29:1535–1540. <https://doi.org/10.1093/annonc/mdy169>
 36. Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roland E (2020) Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. *Oncologist* 25:e589–e597. <https://doi.org/10.1634/theoncologist.2019-0527>
 37. Sugawara S, Inui N, Kanehara M, Morise M, Yoshimori K, Kumagai T, Fukui T, Minato K, Iwashima A, Takeda Y, Kubota K, Saeki T, Tamura T (2019) Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron

- for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. *Cancer* 125:4076–4083. <https://doi.org/10.1002/cncr.32429>
38. Sukaichai S, Ketkaew C, Othaganont N, Pichaya P, Promsuwan P (2022) Efficacy of olanzapine 5 mg versus 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting in patients receiving high emetic risk chemotherapy without neurokinin-1 receptor antagonist. *Asian Pac J Cancer Prev* 23:2137–2143. <https://doi.org/10.31557/APJCP.2022.23.6.2137>
 39. Sun DS, Ko YH, Jin JY, Woo IS, Park SY, Eom YA, Kang JH, Kim HK (2022) Efficacy of granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial. *Korean J Intern Med*. <https://doi.org/10.3904/kjim.2020.359>
 40. Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, Goto K, Takiguchi T, Ohyanagi F, Kogure Y, Nogami N, Nakao M, Takeda K, Azuma K, Nagase S, Hayashi T, Fujiwara K, Shimada T, Seki N, Yamamoto N (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. *Ann Oncol* 27:1601–1606. <https://doi.org/10.1093/annonc/mdw220>
 41. Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. *Int J Clin Oncol* 23:382–388. <https://doi.org/10.1007/s10147-017-1200-4>
 42. Yang LQ, Sun XC, Qin SK, Cheng Y, Shi JH, Chen ZD, Wang QM, Zhang HL, Hu B, Liu B, Zhang QY, Shu YQ, Dong J, Han BH, Wang KM, Dang CX, Li JL, Wang HB, Li BL et al (2017) Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: a randomized, double-blind, phase III study. *Eur J Cancer Care* 26(6):e12668. <https://doi.org/10.1111/ecc.12668>
 43. Yeo W, Lau TKH, Li L, Lai KT, Pang E, Cheung M, Chan VTC, Wong A, Soo WMT, Yeong VTY, Tse T, Lam DCM, Yeung EWM, Ng KPK, Tang NLS, Tong M, Suen JJS, Mo FKF (2020) A randomized study of olanzapine versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. *Breast* 50:30–38. <https://doi.org/10.1016/j.breast.2020.01.005>
 44. Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, Takahashi M, Takano T, Abe T, Kitagawa Y (2019) Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. *Oncologist* 24:e347–e357. <https://doi.org/10.1634/theoncologist.2018-0140>
 45. Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chesarri S, Lanzarotti C, Jordan K, Aapro M (2018) A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of neupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). *Ann Oncol* 29:452–458. <https://doi.org/10.1093/annonc/mdx698>
 46. Zhang L, Qu X, Teng Y, Shi J, Yu P, Sun T, Jingyan W, Zhu Z, Zhang X, Zhao M, Liu J, Jin B, Luo Y, Teng Z, Dong Y, Wen F, An Y, Yuan C, Chen T et al (2017) Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: a randomized, multicenter, double-blind, placebo-controlled phase III trial (CLOG1302 study). *J Clin Oncol* 35:3558–3565. <https://doi.org/10.1200/JCO.2017.72.2538>
 47. Zhang Z, Zhang Y, Chen G, Hong S, Yang Y, Fang W, Luo F, Chen X, Ma Y, Zhao Y, Zhan J, Xue C, Hou X, Zhou T, Ma S, Gao F, Huang Y, Chen L, Zhou N et al (2018) Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy: a network meta-analysis. *Oncologist* 23:603–616. <https://doi.org/10.1634/theoncologist.2017-0378>
 48. Zhao Y, Yang Y, Gao F, Hu C, Zhong D, Lu M, Yuan Z, Zhao J, Miao J, Li Y, Zhu J, Wang C, Han J, Zhao Y, Huang Y, Zhang L (2022) A multicenter, randomized, double-blind, placebo-controlled phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiple-day highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). *eClinicalMedicine*:101771. <https://doi.org/10.20167/eclinm.2022.101771>
 49. Shimomura K, Minatogawa H, Mashiko T, Arioka H, Lihara H, Sugawara M, Hida N, Akiyama K, Nawata S, Tsuboya A, Mishima K, Izawa N, Miyaji T, Honda K, Inada Y, Ohno Y, Katada C, Morita H, Yamaguchi T, Nakajima TE (2021) Placebo-controlled, double-blinded, phase 3 study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy. *Ann Oncol* 32(supplement 5) s1339, LBA63
 50. Herrstedt J, Lindberg S, Petersen PC (2022) Prevention of chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes. *Drugs Aging* 39:1–21. <https://doi.org/10.1007/s40266-021-00909-8>
 51. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. *J Support Oncol* 9:188–195. <https://doi.org/10.1016/j.suponc.2011.05.002>
 52. Mukhopadhyay S, Kwatra G, Alice K P, Badyal D (2017) Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized, controlled study. *Support Care Cancer* 25:145–154. <https://doi.org/10.1007/s00520-016-3386-9>
 53. Gao J, Zhao J, Jiang C, Chen F, Zhao L, Jiang Y, Li H, Wang W, Wu Y, Jin Y, Da L, Liu G, Zhang Y, Li H, Zhang Z, Jin G, Li Q (2022) Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. *Support Care Cancer* 30:6225–6232. <https://doi.org/10.1007/s00520-022-07067-6>
 54. Liu G, Jin Y, Jiang Y, Zhao J, Jiang C, Zhang Z, Zhao L, Li H, Chen F, Wang J, Fan H, Li Z, Jia Y, Jin G, Li Q (2022) A comparison of the efficacy 5 mg olanzapine and aprepitant in the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting. *Int J Clin Practice*. <https://doi.org/10.1155/2022/5954379>
 55. Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B (2018) Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults (review). *Cochrane Database Syst Rev* 9:CD012555. <https://doi.org/10.1002/14651858/CD012555.pub2>
 56. Zhang X-L, Ying J-E (2022) Olanzapine for the prevention and treatment of chemotherapy-induced nausea and vomiting: a review to identify the best way to administer the drug. *Current Oncol* 29:8235–8243. <https://doi.org/10.3390/curroncol29110650>
 57. Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H (2015) Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of singleshot palonosetron and consecutive-day granisetron for

- CINV in a randomized, single-blinded crossover study. *Cancer Med* 4:333–341. <https://doi.org/10.1002/cam4.373>
58. Cass AS, Odinet JS, Valgus JM, Crona DJ (2019) Infusion reactions following administration of intravenous rolapitant in an academic center. *J Oncol Pharm Pract* 25:1776–1783. <https://doi.org/10.1177/1078155218808084>
59. Tyler T, Schultz A, Venturini A, Giuliano C, Bernareggi A, Spezia R, Voisin D, Stella V (2022) Challenges in the development of intravenous neurokinin-1 receptor antagonists. Results of a safety and pharmacokinetics dose-finding, phase 1 study of intravenous fosnetupitant. *Clin Pharmacol Drug Dev* 11:1405–1418. <https://doi.org/10.1002/cpdd.1183>
60. Zhao Y, Zhao B, Chen G, Chen Y, Liao Z, Zhang H, Feng W, Li Y, Weng H, Li W, Zhou Y, Ren B, Lu Y, Chen J, Liu Z, Su Z, Wang W, Zhang L (2023) Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. *Cancer Commun* 43:246–256. <https://doi.org/10.1002/cac2.12397>
61. Ottoboni T, Lauw M, Keller MR, Cravets M, Manhard K, Clendennin N, Quart B (2018) Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects. *Future Oncol* 14:2849–2859. <https://doi.org/10.2217/fon-2018-0311>
62. Dranatsaris G, Moezi M, Dobson K, Phelan R, Blau S (2022) A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. *Support Care Cancer* 30:6649–6658. <https://doi.org/10.1007/s00520-022-07080-7>
63. Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E, Lock M, DeAngelis C, Navari RM (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative metaanalysis and fragility assessment of the literature. *Support Care Cancer* 29:3439–3459. <https://doi.org/10.1007/s00520-020-05935-7>
64. Chow R, Navari RM, Terry B, DeAngeles C, Prsic EH (2022) Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. *Support Care Cancer* 30:1015–1018. <https://doi.org/10.1007/s00520-021-06606-x>
65. Chong MF, Chan A (2018) Thalidomide for delayed chemotherapy-induced nausea and vomiting: where is its place in therapy? *J Clin Oncol* 36:827–828. <https://doi.org/10.1200/JCO.2017.76.4316>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.